CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
Initial blood draw +4 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03665077
NCT03665077N/ACompleted
CompareCT.gov

Pilot Trial to Evaluate Blood and Imaging Based Biomarkers for Aromatase Inhibitor Induced Musculoskeletal Syndrome

University of Arizona·interventional·Posted Sep 11, 2018·Updated Aug 24, 2023

In Brief

A clinical study evaluating Initial blood draw, Initial SWE ultrasound, and 3 other interventions for Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) and Breast Cancer. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 11, 2018
Enrollment StartFeb 28, 2018
Primary CompletionJun 15, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 7.8 years ago

Interventions

Initial blood drawother

At baseline, patients will undergo a blood draw.

Initial SWE ultrasoundother

At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.

Blood draw at three monthsother

Blood drawn at three months to evaluate oxylipins.

Blood draw at six monthsother

Blood drawn at six months to evaluate oxylipins.

SWE ultrasound at six monthsother

SWE ultrasound at six months to evaluate tendon stiffness.